United Therapeutics (UTHR) Income from Continuing Operations (2009 - 2026)

United Therapeutics has disclosed Income from Continuing Operations across 18 years of filings, most recently posting 274900000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 274900000.0, down 14.68% year-over-year; the trailing twelve-month figure through Mar 2026 was 1287400000.0 (up 6.34% YoY), and the FY2025 annual result was 1334700000.0, up 11.68% from the prior year.
• Income from Continuing Operations came in at 274900000.0 for Q1 2026 at United Therapeutics, down from 364300000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 364300000.0 in Q4 2025 to a low of 116000000.0 in Q2 2022.
• The 5-year median for Income from Continuing Operations is 274900000.0 (2026), against an average of 265694117.65.
• Peak annual rise in Income from Continuing Operations reached 747.7% in 2022, while the deepest fall reached 32.79% in 2022.
• United Therapeutics' Income from Continuing Operations stood at 132100000.0 in 2022, then soared by 64.35% to 217100000.0 in 2023, then soared by 38.78% to 301300000.0 in 2024, then rose by 20.91% to 364300000.0 in 2025, then decreased by 24.54% to 274900000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 274900000.0 (Q1 2026), 364300000.0 (Q4 2025), and 338700000.0 (Q3 2025), per Business Quant data.